Global Hemostats Market: Type, Formulation, Application, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

The hemostats market is closely tied to the pace of surgical activity worldwide, reflecting the growing demand for effective bleeding control in an expanding range of procedures. In 2024, the market is valued at approximately US$ 2,884.13 million and is forecasted to grow steadily, reaching an estimated valuation of US$ 4,839.68 million by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 5.92% between 2025 and 2033. One of the key drivers behind this expansion is the increasing adoption of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries.

Regionally, North America continues to dominate the hemostats market in terms of procedural consumption, benefiting from a well-established healthcare infrastructure and high surgical volumes. However, the Asia-Pacific region is rapidly gaining ground, propelled by significant investments in government-funded trauma networks and a surge in laparoscopic surgeries, especially in populous countries like China and India. This growth signals a shift in market dynamics as Asia-Pacific emerges as a vital growth engine for hemostatic product manufacturers seeking to capitalize on increasing surgical activities and expanding healthcare access in the region.

Noteworthy Market Developments

The hemostats market is led by several prominent companies, including Johnson & Johnson, Baxter International, Pfizer Inc., B. Braun SE, and Becton, Dickinson and Company (BD). These industry giants boast a strong global footprint and remain deeply committed to advancing their market positions through vigorous research and development efforts, strategic partnerships, and continuous product innovation.

Baxter International exemplifies this innovation-driven approach with its Applied Hemostasis laboratory, staffed by a team of 50 scientists dedicated to developing next-generation hemostatic solutions. In 2023 alone, this lab filed 42 patent families, focusing on advanced materials such as shear-thinning gelatin and lyoprotected thrombin combinations. These innovations aim to improve the efficacy and application versatility of hemostats, addressing the nuanced needs of modern surgical procedures.

Meanwhile, BD has strategically expanded its portfolio through acquisitions, exemplified by its purchase of Tissuemed for $214 million. This acquisition granted BD access to Tissuemed's ultra-thin polyethylene glycol patch technology, enhancing its product breadth and enabling it to offer more specialized and effective hemostatic options to the market. Such moves demonstrate BD's commitment to strengthening its position through targeted investments in innovative products.

Core Growth Drivers

The rapid growth in minimally invasive surgery (MIS) volumes stands out as the most powerful driver fueling expansion in the hemostats market. According to the International Society for Minimally Invasive Surgery, approximately 108 million laparoscopic, robotic, and endoscopic procedures are expected to be performed globally in 2024. This represents an increase of about 11 million cases compared to 2022, highlighting the accelerating adoption of MIS techniques across a wide range of surgical specialties.

Hemostatic agents are now deployed in roughly one out of every three minimally invasive surgeries, translating to nearly 36 million units utilized in 2024 alone. This widespread integration underscores the vital role hemostats play in enabling safe and efficient MIS procedures. The continued expansion of minimally invasive techniques is expected to sustain strong demand for hemostatic products, further driving innovation and growth within the market

Emerging Opportunity Trends

Scientific interest is increasingly shifting toward hybrid collagen-chitosan hemostats, a trend that is significantly reshaping the competitive dynamics within the hemostats market. These hybrid formulations combine the beneficial properties of collagen with the unique features of chitosan, offering enhanced hemostatic performance and improved tissue compatibility. Between January 2023 and March 2024, the European Database on Medical Devices (EUDAMED) recorded 11 new CE Mark approvals for collagen-chitosan composite products, a stark contrast to the mere three approvals granted for oxidized cellulose-based hemostats during the same period.

In the United States, the Food and Drug Administration (FDA) cleared six collagen-chitosan hybrid hemostats within the same timeframe. Notably, half of these products received Breakthrough Device designation, underscoring their innovative nature and clinical promise. These designations were largely based on rapid clot formation benchmarks demonstrated through preclinical testing, where bleeding times were reduced to under 20 seconds in porcine liver models.

Barriers to Optimization

Rising raw-material prices are significantly impacting profitability within the bovine-collagen-based biosurgicals segment, posing a substantial challenge to the hemostats market in 2024. According to data from the U.S. Department of Agriculture, the cost of medical-grade bovine tendon collagen surged to $19.40 per kilogram in April 2024, up sharply from $13.00 per kilogram in 2022. Although the amount of purified collagen used in each absorbable patch averages just 1.9 grams, this increase translates to a material cost of approximately $0.037 per unit.

Baxter's most recent 10-K filing highlights the financial strain caused by these raw material price hikes, reporting a $94 million year-over-year increase in biomaterial expenditures, driven predominantly by rising bovine collagen costs. This surge has compressed gross margins by roughly $6 per device, a notable figure that directly affects profitability. To counterbalance these increased costs, manufacturers have implemented price adjustments at the SKU level, with hospital group purchasing organization (GPO) catalogs reflecting average price hikes of around $9 per unit.

Detailed Market Segmentation

By Type, the topical category occupies a dominant position in the hemostats market, commanding over 85.46% of the total market share. This prominence is largely attributed to the versatility and convenience that topical hemostatic agents offer across a broad spectrum of surgical workflows. Unlike some hemostatic products that require specialized equipment or ancillary hardware, topical agents can be applied directly to the bleeding site with minimal preparation, making them highly compatible with both open surgeries and minimally invasive procedures.

By formulation, matrices and gels dominate the hemostats market in terms of formulation revenue, accounting for 34.26% of the total market share. Their popularity stems from their unique ability to combine the ease of handling typically associated with topical agents with the flexibility and adaptability of liquids. This hybrid quality makes them particularly well-suited for controlling bleeding in complex surgical fields where blood loss often originates from irregular cavities or delicate, friable parenchymal tissue.

Based on application, orthopedic surgery represents a significant segment of the hemostats market, capturing more than 30.26% of the total market share based on application. This prominence is largely due to the nature of orthopedic procedures, which tend to generate some of the heaviest routine blood loss among elective surgical specialties. As a result, orthopedic theaters are among the most intensive users of hemostatic products, relying heavily on these adjuncts to manage bleeding effectively during complex joint, spine, and trauma fixation surgeries.

By End Users, hospitals hold a commanding position in the hemostats market, capturing over 56.20% of the total market share. This dominance is primarily due to their responsibility for managing the highest acuity cases, which require a broad range of surgical consumables, including hemostatic products. Hospitals also exercise significant control over procurement formularies, enabling them to standardize and streamline the acquisition of essential items to meet the demands of complex surgical procedures.

Segment Breakdown

By Type

• Topical Hemostats
  • Mechanical Hemostats
    • ORC Based
    • Gelatin Based
    • Collagen Based
• Polysaccharide Based Topical Hemostats
  • Active Hemostats
  • Flowable Hemostats
• Topical Thrombin Based Topical Hemostats
• Others

By Formulation

• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats
• Matrix and Gel Hemostats
• Others

By Application

• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Home Care
• Others

By Distribution Channel

• Online
• Offline
  • Direct
  • Distributor

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America

Leading Market Participants

• B.Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Co.
• Gelita Medical GmbH
• Hemostatis LLC
• Integra Life Sciences Holding Corp.
• Johnson and Johnson
• Medtronic PLC
• Pfizer Inc.
• Stryker Corp.
• Teleflex Inc.
• Other Prominent Players